Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaos Corporation (DAC) vs Quest Diagnostics Inc (DGX) Price & Performance

Danaos CorporationTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Danaos Corporation vs Quest Diagnostics Inc — how do they compare? Danaos Corporation trades at $137.89 (market cap $2.46B), while Quest Diagnostics Inc trades at $237.86 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 10.7× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.67%). Which is the better fit depends on your goals.

DACDGX
Market Cap
$2.46B$26.21B
Sector
TechnologyHealth
52-Week High
$143.15$238.50
52-Week Low
$84.05$173.49
Enterprise Value
$2.44B$31.97B
Dividend Yield
2.67%1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaos Corporation

Danaos Corporation (DAC) trades at $137.35, down 0.7% on the day, but maintains strong technical and fundamental momentum. The stock shows a bullish technical signal with key support at $133 and resistance at $138. Fundamentally, DAC demonstrates exceptional profitability with a 51.26% net income margin and attractive valuation metrics including a P/E of 4.57 and P/B of 0.61. Recent Q2 2026 earnings beat expectations with EPS of $7.29 versus $6.80 expected, continuing a pattern of strong quarterly performance.

DAC presents a compelling value opportunity with deep discount to book value and consistent earnings outperformance. The company's record $4.6 billion contracted revenue backlog provides visibility, while quarterly dividends of $0.90 per share enhance shareholder returns. Primary risks include shipping industry cyclicality and capital expenditure requirements for fleet expansion. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's value proposition balanced against sector dynamics.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

Returns comparison

Trailing returns across standard periods

About Danaos Corporation

Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.

Read more on DAC

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX